Covis will market and distribute Zantac Injection in three SKUs, including 2mL, 6mL and 40ml vials, and expects to launch the product in 50mg premixed bags, shortly.
The histamine H2-receptor antagonist is indicated for the treatment of some hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers or as an alternative to the oral dosage form for short-term use.
Covis CEO Bill Collins said by making Zantac Injection available again, the company has responded to current needs.
"Covis can invest the necessary work and focused expertise to reduce distribution interruptions for critical therapies," Collins added.